Supplemental material
Report
A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy
Gerhard FreyResearch & Development, BioAtla Inc, San Diego, CA, USACorrespondence[email protected]
https://orcid.org/0000-0003-2086-4853View further author information
https://orcid.org/0000-0003-2086-4853View further author information, , Haizhen LiuResearch & Development, BioAtla Inc, San Diego, CA, USAhttps://orcid.org/0000-0002-6268-5485View further author information
https://orcid.org/0000-0002-6268-5485View further author information, Charles XingResearch & Development, BioAtla Inc, San Diego, CA, USAhttps://orcid.org/0000-0002-5108-3577View further author information
https://orcid.org/0000-0002-5108-3577View further author information, Christina WheelerResearch & Development, BioAtla Inc, San Diego, CA, USAhttps://orcid.org/0009-0001-0444-5811View further author information
https://orcid.org/0009-0001-0444-5811View further author information, Hwai Wen ChangResearch & Development, BioAtla Inc, San Diego, CA, USAhttps://orcid.org/0000-0001-8666-2002View further author information
https://orcid.org/0000-0001-8666-2002View further author information, William J. BoyleResearch & Development, BioAtla Inc, San Diego, CA, USAhttps://orcid.org/0000-0001-5304-5649View further author information
https://orcid.org/0000-0001-5304-5649View further author information & Jay M. ShortResearch & Development, BioAtla Inc, San Diego, CA, USAhttps://orcid.org/0000-0001-7661-6854View further author information
https://orcid.org/0000-0001-7661-6854View further author information show all